Replies to post #341248 on NorthWest Biotherapeutics Inc (NWBO)

[abeta]

Too many ALIVE patients?

so they need a journal to support it?

Why oh why did they put recurrence - you know - RECURRENCE -
in the thingie thing. And the SAP too

(I'll bet their all partial resections.)

And then there is this -

SA - 20th

methylated MGMT gene, which is present in 40% GBM patients

perspective

Another very interesting thing to note: The interim analyses were blinded. That means, while they saw that patients in the trial survived for a median of 23.1 months at that time (34.7 for patients with a methylated MGMT gene, which is present in 40% GBM patients), which is a vast improvement over historical rates (of 19.6 months for TMZ+Optune and 15.2 months for TMZ alone, see here), they could not know which patients survived longer, SoC+placebo patients or SoC+DCVax-L patients.

If we reached 40% your talking 132 patients
If we reached ~30% your talking 100 patients

Who knows - VAX + TMZ in methylated MGMT might be an eye opener

Stay Tuned